Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses her presentation at American Society of Nephrology’s Kidney Week 2021 on the known and previously established risks associated with rosuvastatin use.
Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses her presentation at American Society of Nephrology’s Kidney Week 2021 on the known and previously established risks associated with rosuvastatin use.
Galindo gave a general overview of his session and explained the new standards of care for chronic kidney disease which he has felt made a great impact on the field.
Mei Ka Fong, PharmD, BCOP, said sunitinib was the first targeted therapy for NETs, although other targeted agents are being investigated.
Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, addresses the questions surrounding the efficacy of perioperative octreotide treatment for patients experiencing a carcinoid crisis.
Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses how CBD and cannabinol can offer potential treatment options as more research is being brought to the forefront on these as integrative medicine.
Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses what octreotide is and how it is used to reduce carcinoid crisis rates or treat a crisis.
NETs can occur almost anywhere in the body, although they are most common in the gastrointestinal tract and lungs.
Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses his presentation at the 2021 NANETS Virtual Symposium on a prospective study of carcinoid crisis with no perioperative octreotide.
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how communication plays a huge role in treatment of neuroendocrine tumors in large cancer centers.
Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses why integrative treatment can help physicians personalize treatments for individuals with NETs and why it is beneficial to improve the quality of life for them.
Mei Ka Fong, PharmD, BCOP, said there are multiple treatment approaches for patients with NETs.
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses what kind of support services at large cancer centers can help individuals with neuroendocrine tumors with their treatment.
Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center, discusses how integrative medicine can help treatment of neuroendocrine tumors in combination with other treatments.
Mark Garofoli, director of Experiential Learning Program at WVU School of Pharmacy, discusses his CPhT 2021 conference presentation regarding the role and impact of pharmacy technicians on opioids in the pharmacy.
Emily Holcomb, PharmD, BCPS, ISMP Safe Medication Management Fellow, discusses her CPhT 2021 conference presentation regarding targeted medication safety best practices.
Amy Summers, PharmD, BCSCP, consultant at Restore Health Consulting, discusses her CPhT 2021 conference presentation regarding proposed changes to the USP <795> and <797>.
Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses his SOHO 2021 conference presentation on prognostication and treatment of Burkitt lymphoma in the modern era.
Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains the initial management process for oncologic emergencies, the treatments currently available, and treatments coming in the drug pipeline.
An overview of this year's NCPA Annual Convention, including highlights from sessions about pharmacy technicians, point-of-care testing, misinformation, and new drugs and clinical pearls in community pharmacy.
Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains what the most common complications from cancer treatment are that can lead to oncologic emergencies and how can they be identified.
Melissa Pein, a pharmacy technician supervisor at Children’s Mercy Kansas City Hospital, discusses her CPhT 2021 conference presentation regarding pharmacy technicians and the role they play in vaccinations
Meredith Ayers, CPhT, pharmacy technician at Bremo Pharmacy and presenter at the annual NCPA Convention 2021, discusses the expanding role of pharmacy technicians.
Pezzino discussed new specific prescriptions and treatments compared to current treatment modalities, indications and routes of administration of new drugs in the community setting, and important pharmacokinetic properties of these new drugs.
Ching discussed topics such as additional testing services, recommendations for point-of-care services, and strategies to help increase point-of-care testing services.
Anjanette Wyatt, PharmD, said pharmacists can play a major role in helping patients distinguish trustworthy facts from misinformation.
National Community Pharmacists Association (NCPA) President Brian Caswell, RPh, said he is incredibly proud of the work community pharmacists have done over the past year.
Jameshia Below, PharmD, assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains how oncologic emergencies present in patients, and how each type can be recognized.
Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains what oncologic emergencies are and how they are classified.
Patients with relapsed or refractory chronic lymphocytic leukemia are generally divided by those exposed to Bruton's tyrosine kinase inhibitors (BTKi), patients relapsing after venetoclax, and patients relapsing after BTKi and B-cell lymphoma-2 inhibitors.
